Is Rhophylac® a new product?
A. No. Although not approved for ITP until 2007, Rhophylac® was introduced in Europe in 1996 and received approval from the US Food & Drug Administration (FDA) in 2004 for the suppression of rhesus (Rh) isoimmunization in pregnancy, obstetric conditions, and in incompatible transfusions in Rh-negative individuals. More than 1.5 million doses have been given worldwide with no confirmed cases of viral transmission.